WeissLaw LLP announces that a class action has been filed in the United States District Court for the Southern District of New York against Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (TKAI) and certain Company officers, for among other things, violation of sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 (the “Exchange Act”). The class action seeks …